Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase: The ACTION Study

NCT04064346 is registered in ClinicalTrials.gov with Palladio Biosciences as lead sponsor.

NCT NCT04064346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04064346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase: The ACTION Study
Lead sponsor
Palladio Biosciences
Phase
Phase 3
Overall status
Terminated
Start date
October 28, 2021
Completion date
August 3, 2022
Enrollment
12 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

adpkd, autosomal dominant polycystic kidney